Bleakley Financial Group LLC Has $263,000 Holdings in Moderna, Inc. (NASDAQ:MRNA)

Bleakley Financial Group LLC cut its stake in Moderna, Inc. (NASDAQ:MRNA) by 18.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,934 shares of the company’s stock after selling 907 shares during the period. Bleakley Financial Group LLC’s holdings in Moderna were worth $263,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC acquired a new stake in Moderna during the second quarter worth about $26,000. Cedar Wealth Management LLC lifted its position in shares of Moderna by 45.0% in the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. acquired a new stake in shares of Moderna during the 1st quarter worth approximately $32,000. Family Firm Inc. bought a new stake in shares of Moderna during the second quarter valued at approximately $33,000. Finally, Bank & Trust Co acquired a new position in shares of Moderna in the second quarter valued at $36,000. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of recent research reports. Evercore ISI reiterated an “in-line” rating and set a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th. Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Bank of America decreased their price objective on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a report on Friday, September 13th. Finally, Barclays lowered their price objective on Moderna from $155.00 to $125.00 and set an “overweight” rating on the stock in a research note on Monday, September 16th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Moderna has an average rating of “Hold” and a consensus target price of $97.18.

Moderna Stock Down 0.0 %

Shares of NASDAQ:MRNA opened at $53.39 on Thursday. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The firm has a market cap of $20.46 billion, a P/E ratio of -3.41 and a beta of 1.66. Moderna, Inc. has a 12 month low of $52.77 and a 12 month high of $170.47. The company’s 50-day moving average price is $69.03 and its two-hundred day moving average price is $103.55.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. During the same period in the previous year, the business posted ($3.62) EPS. The company’s quarterly revenue was down 29.9% compared to the same quarter last year. As a group, research analysts forecast that Moderna, Inc. will post -9.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at approximately $682,754. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 715 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 18,184 shares of company stock worth $2,037,931. Insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.